Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(5):881–889. doi: 10.1038/sj.bjc.6690780

Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas

I Cruz 1,2, C J L M Meijer 1, J M M Walboomers 1, P J F Snijders 1, I Van der Waal 2
PMCID: PMC2374311  PMID: 10555762

Abstract

Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells use the secretory pathway of perforin/granzymes to kill their target cells. In contrast to NK cells, CTL responses are MHC class I restricted. In this study we analysed the relative activation of CTL and NK cells in relation with MHC class I expression on oral squamous cell carcinomas (OSCCs). MHC class I expression was investigated in 47 OSCCs by immunohistochemistry using HCA2, HC10 and β2-m antibodies. The presence of CTLs, NK cells, and its activation, was investigated in 21 of these OSCCs using respectively, CD8, CD57 and GrB7 antibodies. The Q-Prodit measuring system was used for quantification of cytotoxic cells. All OSCCs showed weak or absent staining of β2-m on the cell surface. The absence of β2-m was significantly associated with absent expression of MHC class I heavy chain as detected by HC10 antibody (P = 0.004). In tumour infiltrates CTLs always outnumbered NK cells, as reflected by the ratio CD57/CD8 being always inferior to one (mean: 0.19; SD: 0.15). The proportion of activated cytotoxic cells as detected by granzyme B expression was generally low (mean: 8.6%; SD 8.9). A clear correlation between MHC class I expression and the relative proportion of NK cells/CTLs was not found. This study shows that the majority of OSCCs show weak or absent expression of MHC class I molecules on the cell surface, possibly due to alterations in the normal β2-m pathway. The low proportion of granzyme B-positive CTLs/NK cells indicates that the secretory pathway of cytotoxicity is poor in these patients. The lack of correlation between MHC class I expression and CTL/NK cell activation as detected by granzyme B expression suggests that, next to poor antigen presentation, also local factors seem to determine the final outcome of the cytotoxic immune response. © 1999 Cancer Research Campaign

Keywords: oral carcinoma, MHC class I, β2-microglobulin, CTLs, NK cells, granzyme B

Full Text

The Full Text of this article is available as a PDF (930.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998 Jun 1;160(11):5669–5675. [PubMed] [Google Scholar]
  2. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol. 1997 Jan;4(1):32–40. doi: 10.1097/00062752-199704010-00006. [DOI] [PubMed] [Google Scholar]
  3. Bicknell D. C., Rowan A., Bodmer W. F. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4751–4755. doi: 10.1073/pnas.91.11.4751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bobrow M. N., Harris T. D., Shaughnessy K. J., Litt G. J. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods. 1989 Dec 20;125(1-2):279–285. doi: 10.1016/0022-1759(89)90104-x. [DOI] [PubMed] [Google Scholar]
  5. Bontkes H. J., de Gruijl T. D., Walboomers J. M., van den Muysenberg A. J., Gunther A. W., Scheper R. J., Meijer C. J., Kummer J. A. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer. 1997;76(10):1353–1360. doi: 10.1038/bjc.1997.560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brinkhuis M., Mogensen O., Bichel P., Baak J.P.A. The significance of differences in prognostic value of quantitative pathologic features in FIGO stage III and IV serous adenocarcinoma of the ovary between a group of Danish patients and other groups. Int J Gynecol Cancer. 1995 Sep;5(5):355–360. doi: 10.1046/j.1525-1438.1995.05050355.x. [DOI] [PubMed] [Google Scholar]
  7. Chambers C. A., Allison J. P. Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun;9(3):396–404. doi: 10.1016/s0952-7915(97)80087-8. [DOI] [PubMed] [Google Scholar]
  8. Chapman T. L., Bjorkman P. J. Characterization of a murine cytomegalovirus class I major histocompatibility complex (MHC) homolog: comparison to MHC molecules and to the human cytomegalovirus MHC homolog. J Virol. 1998 Jan;72(1):460–466. doi: 10.1128/jvi.72.1.460-466.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cruz I. B., Snijders P. J., Meijer C. J., Braakhuis B. J., Snow G. B., Walboomers J. M., van der Waal I. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol. 1998 Apr;184(4):360–368. doi: 10.1002/(SICI)1096-9896(199804)184:4<360::AID-PATH1263>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  10. D'Urso C. M., Wang Z. G., Cao Y., Tatake R., Zeff R. A., Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991 Jan;87(1):284–292. doi: 10.1172/JCI114984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ding L., Linsley P. S., Huang L. Y., Germain R. N., Shevach E. M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993 Aug 1;151(3):1224–1234. [PubMed] [Google Scholar]
  12. Froelich C. J., Dixit V. M., Yang X. Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. Immunol Today. 1998 Jan;19(1):30–36. doi: 10.1016/s0167-5699(97)01184-5. [DOI] [PubMed] [Google Scholar]
  13. Gómez J., González A., Martínez-A C., Rebollo A. IL-2-induced cellular events. Crit Rev Immunol. 1998;18(3):185–220. [PubMed] [Google Scholar]
  14. Klein E., Klein G., Nadkarni J. S., Nadkarni J. J., Wigzell H., Clifford P. Surgace IgM specificity on cells derived from a Burkitt's lymphoma. Lancet. 1967 Nov 18;2(7525):1068–1070. doi: 10.1016/s0140-6736(67)90340-6. [DOI] [PubMed] [Google Scholar]
  15. Kos F. J., Engleman E. G. Immune regulation: a critical link between NK cells and CTLs. Immunol Today. 1996 Apr;17(4):174–176. doi: 10.1016/0167-5699(96)80616-5. [DOI] [PubMed] [Google Scholar]
  16. Kummer J. A., Kamp A. M., Tadema T. M., Vos W., Meijer C. J., Hack C. E. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol. 1995 Apr;100(1):164–172. doi: 10.1111/j.1365-2249.1995.tb03619.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kummer J. A., Kamp A. M., van Katwijk M., Brakenhoff J. P., Radosević K., van Leeuwen A. M., Borst J., Verweij C. L., Hack C. E. Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods. 1993 Jul 6;163(1):77–83. doi: 10.1016/0022-1759(93)90241-x. [DOI] [PubMed] [Google Scholar]
  18. Kägi D., Ledermann B., Bürki K., Zinkernagel R. M., Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 1996;14:207–232. doi: 10.1146/annurev.immunol.14.1.207. [DOI] [PubMed] [Google Scholar]
  19. Lanier L. L., Phillips J. H. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today. 1996 Feb;17(2):86–91. doi: 10.1016/0167-5699(96)80585-8. [DOI] [PubMed] [Google Scholar]
  20. Lichtenstein A., Zighelboim J., Dorey F., Brossman S., Fahey J. L. Comparison of immune derangements in patients with different malignancies. Cancer. 1980 Apr 15;45(8):2090–2095. doi: 10.1002/1097-0142(19800415)45:8<2090::aid-cncr2820450816>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  21. Mingari M. C., Moretta A., Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today. 1998 Apr;19(4):153–157. doi: 10.1016/s0167-5699(97)01236-x. [DOI] [PubMed] [Google Scholar]
  22. Parham P. Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Am J Reprod Immunol. 1995 Jul;34(1):10–19. doi: 10.1111/j.1600-0897.1995.tb00914.x. [DOI] [PubMed] [Google Scholar]
  23. Prime S. S., Pitigala-Arachchi A., Crane I. J., Rosser T. J., Scully C. The expression of cell surface MHC class I heavy and light chain molecules in pre-malignant and malignant lesions of the oral mucosa. Histopathology. 1987 Jan;11(1):81–91. doi: 10.1111/j.1365-2559.1987.tb02611.x. [DOI] [PubMed] [Google Scholar]
  24. Reichert T. E., Day R., Wagner E. M., Whiteside T. L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998 Dec 1;58(23):5344–5347. [PubMed] [Google Scholar]
  25. Rosa F., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M. The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J. 1983;2(2):239–243. doi: 10.1002/j.1460-2075.1983.tb01412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stam N. J., Spits H., Ploegh H. L. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 1986 Oct 1;137(7):2299–2306. [PubMed] [Google Scholar]
  27. Stam N. J., Vroom T. M., Peters P. J., Pastoors E. B., Ploegh H. L. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol. 1990;2(2):113–125. doi: 10.1093/intimm/2.2.113. [DOI] [PubMed] [Google Scholar]
  28. Wanebo H. J., Jun M. Y., Strong E. W., Oettgen H. T-cell deficiency in patients with squamous cell cancer of the head and neck. Am J Surg. 1975 Oct;130(4):445–451. doi: 10.1016/0002-9610(75)90482-1. [DOI] [PubMed] [Google Scholar]
  29. Whiteside T. L., Chikamatsu K., Nagashima S., Okada K. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res. 1996 Jul-Aug;16(4C):2357–2364. [PubMed] [Google Scholar]
  30. Yokoyama W. M. Natural killer cell receptors. Curr Opin Immunol. 1995 Feb;7(1):110–120. doi: 10.1016/0952-7915(95)80036-0. [DOI] [PubMed] [Google Scholar]
  31. van den Broek M. F., Kägi D., Zinkernagel R. M., Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol. 1995 Dec;25(12):3514–3516. doi: 10.1002/eji.1830251246. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES